Audrey Gross; Head of Corporate Communications; Aadi Bioscience Inc. Dave Lennon; President, Chief Executive Officer, Principal Executive Officer; Aadi Bioscience In ...

New name reflects focus on accelerating portfolio of advanced ADC therapies with speed, agility and precision Upon closing of strategic transactions, cash expected ...

HWK-007 represents a differentiated opportunity to potentially be among the first next-wave ADCs in clinical development for high PTK7 expressing cancers. HWK-007 is being evaluated in IND ...

It will also support initial trials of CD70-targeted PRO1160, PTK7-targeted PRO1107, and bispecific ADC PRO1286. New investors in the round included Nextech Invest, T Rowe Price Associates ...